Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa - Significance of sampling

Pathology Research and Practice

Volumn 204, Issue 5, 2008, Pages 285-294

  Werther, Meike ^a   Saure, Christoph ^b   Pahl, René ^c   Schorr, Friedrich ^d   Rüschoff, Josef ^a   Alles, Jens Uwe ^e   Heinmöller, Ernst ^a  

^a Institut für Pathologie Nordhessen   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c Office of Engineering and Biostatistics   (Germany)

^d KLINIKUM KASSEL   (Germany)

^e Agaplesion Evangelisches Krankenhaus Mittelhessen   (Germany)

Author keywords

Barrett's mucosa; Biopsy samples; Molecular analysis; Sampling error; Surveillance

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CLINICAL ARTICLE; DISEASE MARKER; DISEASE SURVEILLANCE; DYSPLASIA; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MALE; MICROSATELLITE MARKER; MOLECULAR DYNAMICS; MOLECULAR GENETICS; SAMPLING ERROR; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; GENES, P16; GENES, P53; GENES, TUMOR SUPPRESSOR; GERMANY; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUCOUS MEMBRANE; MUTATION; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 41449094454     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.12.011     Document Type: Article

References (44)

1. Alikhan M., Rex D., Khan A., Rahmani E., Cummings O., and Ulbright T.M. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 50 (1999) 23-26
2. Barrett M.T., Sanchez C.A., Galipeau P.C., Neshat K., Emond M., and Reid B.J. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13 (1996) 1867-1873
3. Barrett M.T., Schutte M., Kern S.E., and Reid B.J. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res. 56 (1996) 4351-4353
4. Barrett M.T., Sanchez C.A., Prevo L.J., Wong D.J., Galipeau P.C., Paulson T.G., Rabinovitch P.S., and Reid B.J. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet. 22 (1999) 106-109
5. Bian Y.S., Osterheld M.C., Bosman F.T., Benhattar J., and Fontolliet C. p53 Gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 14 (2001) 397-403
6. Boynton R.F., Blount P.L., Yin J., Brown V.L., Huang Y., Tong Y., McDaniel T., Newkirk C., Resau J.H., and Raskind W.H. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc. Natl. Acad. Sci. 89 (1992) 3385-3388
7. Dietmaier W., Wallinger S., Bocker T., Kullmann F., Fishel R., and Rüschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 57 (1997) 4749-4756
8. Dietmaier W., Hartmann A., Wallinger S., Heinmoller E., Kerner T., Endl E., Jauch K.W., Hofstadter F., and Rüschoff J. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am. J. Pathol. 154 (1999) 83-95
9. Doak S.H., Jenkins G.J., Parry E.M., D'Souza F.R., Griffiths A.P., Toffazal N., Shah V., Baxter J.N., and Parry J.M. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 52 (2003) 623-628
10. Dolan K., Morris A.L., Gosney J.R., Field J.K., and Sutton R. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. J. Gastroenterol. Hepatol. 18 (2003) 683-689
11. Falk G.W. Barrett's esophagus. Gastroenterology 122 (2002) 1569-1591
12. Fang M., Lew E., Klein M., Sebo T., Su Y., and Goyal R. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. Am. J. Gastroenterol. 99 (2004) 1887-1894
13. Galipeau P.C., Prevo L.J., Sanchez C.A., Longton G.M., and Reid B.J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J. Natl. Cancer Inst. 91 (1999) 2087-2095
14. Goldblum J.R., and Lauwers G.Y. Dysplasia arising in Barrett's esophagus: diagnostic pitfalls and natural history. Semin. Diagn. Pathol. 19 (2002) 12-19
15. Hage M., Siersema P.D., Vissers K.J., Dinjens W.N., Steyerberg E.W., Haringsma J., Kuipers E.J., and van Dekken H. Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci. Int. J. Cancer 118 (2006) 155-160
16. In: Hamilton S.R., and Aaltonen L.A. (Eds). World Health Organization of Tumours. Pathology and Genetics of Tumours of the Digestive System (2000), IARC Press, Lyon
17. Hardie L.J., Darnton S.J., Wallis Y.L., Chauhan A., Hainaut P., Wild C.P., and Casson A.G. p16 Expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 217 (2005) 221-230
18. Heinmöller E., Renke B., Beyser K., Dietmaier W., Langner C., and Rüschoff J. Pitfalls in diagnostic molecular pathology - significance of sampling error. Virchows Arch. 439 (2001) 504-511
19. Heinmöller E., Schlake G., Renke B., Liu Q., Hill K.A., Sommer S.S., and Rüschoff J. Microdissection and molecular analysis of single cells or small cell clusters in pathology and diagnosis - significance and challenges. Anal. Cell Pathol. 24 (2002) 125-134
20. Heinmöller E., Qiang L., Sun Y., Schlake G., Hill K.A., Weiss L.M., and Sommer S.S. Toward efficient analysis of mutations in single cells from ethanolfixed, paraffin-embedded, and immunohistochemically-stained tissues. Lab. Invest. 82 (2002) 443-453
21. Jankowski J.A., Harrison R.F., Perry I., Balkwill F., and Tselepis C. Barrett's metaplasia. Lancet 356 (2000) 2079-2085
22. Lai L.A., Paulson T.G., Li X., Sanchez C.A., Maley C., Odze R.D., Reid B.J., and Rabinovitch P.S. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46 (2007) 532-542
23. Levine D.S., Haggitt R.C., Blount P.L., Rabinovitch P.S., Rusch V.W., and Reid B.J. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 105 (1993) 40-50
24. Maley C.C., Galipeau P.C., Li X., Sanchez C.A., Paulson T.G., Blount P.L., and Reid B.J. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 64 (2004) 7629-7633
25. Maley C.C., Galipeau P.C., Li X., Sanchez C.A., Paulson T.G., and Reid B.J. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64 (2004) 3414-3427
26. Montgomery E., Bronner M.P., Goldblum J.R., Greenson J.K., Haber M.M., Hart J., Lamps L.W., Lauwers G.Y., Lazenby A.J., Lewin D.N., Robert M.E., Toledano A.Y., Shyr Y., and Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 32 (2001) 368-378
27. Morales T.G., and Sampliner R.E. Barrett's esophagus: update on screening, surveillance, and treatment. Arch. Intern. Med. 159 (1999) 1411-1416
28. Ormsby A.H., Kilgore S.P., Goldblum J.R., Richter J.E., Rice T.W., and Gramlich T.L. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: implications for patient treatment and preventive strategies in Barrett's esophagus. Mod. Pathol. 13 (2000) 614-620
29. Powell J., and McConkey C.C. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur. J. Cancer Prev. 1 (1992) 265-269
30. Prevo L.J., Sanchez C.A., Galipeau P.C., and Reid B.J. p53-Mutant clones and field effects in Barrett's esophagus. Cancer Res. 59 (1999) 4784-4787
31. Reid B.J., Haggitt R.C., Rubin C.E., Roth G., Surawicz C.M., VanBelle G., Lewin K., Weinstein W.M., Antonioli D.A., Goldman H., MacDonald W., and Owen D. Observer variation in the diagnosis of high grade dysplasia in Barrett's esophagus. Hum. Pathol. 19 (1988) 166-178
32. Reid B.J., Blount P.L., Feng Z., and Levine D.S. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am. J. Gastroenterol. 95 (2000) 3089-3096
33. Reid B.J., Levine D.S., Longton G., Blount P.L., and Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 95 (2000) 1669-1676
34. Reid B.J., Blount P.L., and Rabinovitch P.S. Biomarkers in Barrett's esophagus. Gastrointest. Endosc. Clin. N. Am. 13 (2003) 369-397
35. Riegman P.H., Vissers K.J., Alers J.C., Geelen E., Hop W.C., Tilanus H.W., and van Dekken H. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res. 61 (2001) 3164-3170
36. Romagnoli S., Roncalli M., Graziani D., Cassani B., Roz E., Bonavina L., Peracchia A., Bosari S., and Coggi G. Molecular alterations of Barrett's esophagus on microdissected endoscopic biopsies. Lab. Invest. 81 (2001) 241-247
37. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American college of gastroenterology. Am. J. Gastroenterol. 93 (1998) 1028-1032
38. Sampliner R.E. Practice parameters committee of the American college of gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 97 (2002) 1888-1895
39. Schlegel J., Bocker T., Zirngibl H., Hofstädter F., and Rüschoff J. Detection of microsatellite instability in human colorectal carcinomas using a nonradioactive PCR-based sreening method. Virchows Arch. 426 (1995) 223-227
40. Skacel M., Petras R.E., Gramlich T.L., Sigel J.E., Richter J.E., and Goldblum J.R. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 95 (2000) 3383-3387
41. Souza R.F., Morales C.P., and Spechler S.J. A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol. Ther. 15 (2001) 1087-1100
42. Stein H.J. Esophageal cancer: screening and surveillance. Results of a consensus conference held at the VIth world congress of the International society of the Esophagus. Dis. Esophagus 9 (1996) S3-S19
43. Tytgat G.N.J., and Hameeteman W. The neoplastic potential of columnar-lined (Barrett) esophagus. World J. Surg. 16 (1992) 308-312
44. Weston A.P., Banerjee S.K., Sharma P., Tran T.M., Richards R., and Cherian R. p53 Protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am. J. Gastroenterol. 96 (2001) 1355-1362